ClinicalTrials.gg
Active, not recruitingNCT05382156LINC6Updated Nov 20, 2025

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

An observational study in Endogenous Cushing's Syndrome, sponsored by RECORDATI GROUP. Active, not recruiting at 43 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by RECORDATI GROUP · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
206
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.

Enrollment
12th of 23
206 · median 206
Started
2022
with 2 others
Observational
24 of 58
4 open now
Primary completion
2027-06
later than 3 of 16 live
Registered
45th of 58
by date
Lead sponsor
4 of 58
RECORDATI GROUP

Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 12th largest by enrollment of the 23 observational ones that give a count, is one of 3 that started in 2022, is one of 24 observational ones, reaches primary completion later than 3 of the 16 other live ones, and was the 45th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Cushing Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome

Read the detailed description

This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome. This study is observational in nature and does not impose a therapy protocol, diagnostic/therapeutic interventions or a visit schedule.

Patients with endogenous Cushing's Syndrome who are treated with osilodrostat alone or in combination with other therapies will be considered eligible for study enrolment. Each patient enrolled in the study will be followed up for 3 years from study entry. Patients who discontinue prior to the end of the 3-year period will be followed-up for 3 months after discontinuation of osilodrostat and will be included in the analysis.

The total number of patients enrolled in this study will be approximately 201. Assuming a recruitment period of 3 years, the total study duration from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) will be 6 years. The maximum duration for the individual patient is 3 years.

03

Conditions studied

  • Endogenous Cushing's Syndrome

Browse trials for

Keywords

  • Cushing's syndrome
  • Osilodrostat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The patient population will consist of adult male and female patients with endogenous Cushing's Syndrome. Eligible patients for the study must be treated with osilodrostat. Investigators need to ensure that patients enrolled in this study meet the study inclusion and exclusion criteria listed in the protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained prior to registration of any patient data
  • Male or female patients aged 18 years or older with endogenous CS treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening.

Exclusion criteria

Exclusion Criteria:

  • Patients with exogenous CS
  • Patients with Pseudo CS
  • Patients participating in an interventional clinical trial with an drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
206 participants (actual)
Patient registry
No

Groups and cohorts

  • Osilodrostat

    Osilodrostat - tablets of 1mg, 5mg, 10mg - based on patients needs - up to 3 years

    Drug: Osilodrostat

Interventions

  • oral administration of Osilodrostat tablets at different doses according to patient's need

    Also known as: Isturisa

06

What researchers measure

Primary outcomes

  1. Incidence of osilodrostat-related adverse events and serious adverse events

    Number of participants with Adverse Events and Serious Adverse Events

    Time frame: 3 years of treatment with osilodrostat

Secondary outcomes

  1. Short and long-term efficacy of osilodrostat

    Complete response rate: proportion of enrolled patients with mean Urinary Free Cortisol (mUFC) ≤ ULN

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years

  2. Short and long-term efficacy of osilodrostat

    Partial response rate: proportion of enrolled patients with ≥ 50% reduction from baseline in mean urinary free cortisol (mUFC), (but mUFC \> ULN)

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years

  3. Short and long-term efficacy of osilodrostat

    Overall response rate: proportion of enrolled patients with mean urinary free cortisol (mUFC) ≤ ULN or at least 50% reduction from baseline

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years

  4. Changes in pituitary tumour size

    Actual and percentage change from baseline in pituitary tumour size

    Time frame: at baseline before treatment start, after 6 months of treatment, then every 12 months through study completion up to three years

  5. Incidence of Adverse Events (Safety and Tolerability)

    Incidence of adverse events and laboratory abnormalities using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale (version 5.0).

    Time frame: 3 years of treatment with osilodrostat

  6. Change of mean urinary free cortisol (mUFC)

    Actual and percentage change from baseline in mean urinary free cortisol (mUFC)

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  7. Change of Serum Cortisol

    Actual and percentage change from baseline in Serum Cortisol

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  8. Change of Late Salivary Cortisol

    Actual and percentage change from baseline in Late Salivary Cortisol

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  9. Change of adrenocorticotropic hormone (ACTH)

    Actual and percentage change from baseline in adrenocorticotropic hormone (ACTH)

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  10. Normalization of Serum Cortisol

    Proportion of patients achieving normalisation of Serum Cortisol

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  11. Normalization of Late Salivary Cortisol

    Proportion of patients achieving normalisation of Late Salivary Cortisol

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  12. Normalization of adrenocorticotropic hormone (ACTH)

    Proportion of patients achieving normalisation of adrenocorticotropic hormone (ACTH)

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  13. Change in Fasting Glucose

    Actual and percentage change from baseline in fasting glucose

    Time frame: at baseline before treatment start, then every 3 months through study completion up to three years

  14. Change in HbA1c

    Actual and percentage change from baseline in HbA1c

    Time frame: at baseline before treatment start, then every 3 months through study completion up to three years

  15. Change in Fasting Lipid Profile

    Actual and percentage change from baseline in Fasting Lipid Profile

    Time frame: at baseline before treatment start, then every 3 months through study completion up to three years

  16. Change in Serum Insulin

    Actual and percentage change from baseline in Serum Insulin

    Time frame: at baseline before treatment start, then every 3 months through study completion up to three years

  17. Change in Blood Pressure

    Actual and percentage change from baseline in Blood Pressure

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  18. Change in Body Weight

    Actual and percentage change from baseline in Body Weight

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  19. Change in Body Mass Index (BMI)

    Actual and percentage change from baseline in Body Mass Index (BMI)

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  20. Change in Waist Circumference

    Actual and percentage change from baseline in Waist Circumference

    Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years

  21. Change in Facial Rubor

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Facial Rubor

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  22. Change in Hirsutism

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Hirsutism

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  23. Change in Striae

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Striae

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  24. Change in Supraclavicular fat pad

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Supraclavicular fat pad

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  25. Change in Dorsal fat pad

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Dorsal fat pad

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  26. Change in Proximal muscle wasting (atrophy)

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Proximal muscle wasting (atrophy)

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  27. Change in Central (abdominal) obesity

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Central (abdominal) obesity

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  28. Change in Ecchymoses (bruises)

    Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Ecchymoses (bruises)

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  29. Changes in Patient-Reported Outcome (PRO) questionnaire Cushing Quality of Life (QoL)

    Actual and percentage change from baseline in score of PRO questionnaire CushingQoL. The minimum and maximum values are 12 and 60 respectively, where higher score means a better outcome

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  30. Changes in Patient-Reported Outcome (PRO) questionnaire Euro Quality of Life (EQ) - 5 Dimensions (5D) - 5 Levels (5L)

    Actual and percentage change from baseline in score of PRO questionnaire EQ-5D-5L. The minimum and maximum values for the questions are 11111 and 55555 respectively, where higher score is a worst outcome. For the visual analogue scale minimum and maximum values are 0 and 100 respectively, where higher score means a better outcome

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  31. Changes in Patient-Reported Outcome (PRO) questionnaire Beck Depression Inventory II (BDI-II)

    Actual and percentage change from baseline in score of PRO questionnaire BDI-II. The minimum and maximum values are 1 and 63 respectively, where higher score means a worse outcome

    Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

  32. Changes in Patient-Reported Outcome (PRO) questionnaire Patient Global Impression of Change (PGIC)

    Actual and percentage change in score of PRO questionnaire PGIC. The minimum and maximum values of the question are 1 and 7 respectively, where higher score means a better outcome. For the visual analogue scale minimum and maximum values are 0 and 10 respectively, where higher score means a worse outcome

    Time frame: after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years

07

Study locations

43 sites
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jun 2027, 60 months after the start.

Of 31 observational studies under Cushing Syndrome, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 85. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2022
First posted
May 19, 2022
StartActual
Jun 13, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05382156
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jun 13, 2022
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Mario Maldonado, MD
study chair · Recordati AG - Head of Clinical Development

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion